logo-loader
viewe-Therapeutics PLC

e-Therapeutics continuing to convert business development into cash generating partnerships

e-Therapeutics PLC's (LON:ETX) Ray Barlow says they're actively engaged in exploring all organic and non-organic opportunities that have the potential to create incremental value for its shareholders.

He adds that multiple proposals for its artificial intelligence-based drug research products have been sent to potential partners and customers.

Quick facts: e-Therapeutics PLC

Price: 13.625 GBX

AIM:ETX
Market: AIM
Market Cap: £57.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 makes early rally as airline losses set to total...

Headlines from the Proactive UK newsroom. The FTSE 100 rallied early on after two days of losses with travel groups leading the way. The blue-chip index was up 30 points at 6,366. Airline losses will total around US$84bn this year according to the International Air Transport Association....

on 10/6/20

2 min read